A new
approach for the payment for the provided treatment:
Dutch Health Minister Edith Schippers has
announced that, starting with Novartis' asthma drug Xolair (omalizumab), the
national health insurance council will pay for some new drugs only if they produce
a measurable effect on patients' health.
If they do not, their costs will be
reclaimed from the manufacturer, said the Minister, giving details of the new
scheme, which the council - the College van Zorgerzekringen (CVZ) - has said
will be the first time that the cost of a medicine will depend on the effects
of the treatment.
The scheme is being introduced on the
advice of the CVZ, which has reported that Xolair, costing 16,000 euros per
patient per year, produces no effect in 30% of patients.
Well, why
not? Why should patients and society pay to Big Pharma for inefficient crap?
The CVZ says that it already has an
agreement in place with Novartis, clinicians and patients for the "no cure
no pay" scheme, and that it expects the initiative to save up to 2 million
euros a year.
No balls - no babies!
No comments:
Post a Comment